75 results found.

Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, G Clinical Trial using Rindopepimut (CDX-110) with GM-CSF; Temozolomide; KLH

Celldex Therapeutics - Recruiting 18 years or older.
- An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma.
Rindopepimut (CDX-110) with GM-CSF; Temozolomide; KLH

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Glioblastoma Clinical Trial using Selinexor

Karyopharm Therapeutics, Inc - Recruiting 18 years or older.
- A Phase II, Two-tier Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation Therapy and Temozolomide.
Selinexor

Childhood Mixed Glioma, Untreated Childhood Anaplastic Astrocytom Clinical Trial using veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, G Clinical Trial using Bevacizumab; Rindopepimut (CDX-110) with GM-CSF; KLH

Celldex Therapeutics - Recruiting 18 years or older.
- A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma.
Bevacizumab; Rindopepimut (CDX-110) with GM-CSF; KLH

Brain Cancer Clinical Trial using Vorinostat; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma.
Vorinostat; Bevacizumab

Glioblastoma, or Recurrent Metastatic Cancer to the Brain Clinical Trial using ExAblate 4000

InSightec - Recruiting 18 years to 70 years.
- A Feasibility Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Lesions.
ExAblate 4000

Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood A Clinical Trial using WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 37 Months to 21 years.
- A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

Glioblastoma, Glioma Clinical Trial using GDC-0084

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
GDC-0084

Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendrogliom Clinical Trial using Toca 511; 5-FC

Tocagen Inc. - Recruiting 18 years or older.
- A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma.
Toca 511; 5-FC

Glioblastoma Clinical Trial using aldoxorubicin

CytRx - Recruiting 18 years or older.
- An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide.
aldoxorubicin

Malignant Gliomas Clinical Trial using CT-011

Hadassah Medical Organization - Recruiting 3 years to 90 years.
- A Phase I/ II Clinical Trial of CT-011 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme.
CT-011

Recurrent Supratentorial Glioblastoma Multiforme, GBM, or Gliobla Clinical Trial using Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)

Duke University - Recruiting 18 years or older.
- Dose-finding and Safety Study of PVSRIPO Against Recurrent Glioblastoma.
Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)

Recurrent Glioblastoma Clinical Trial using Nivolumab; Ipilimumab; Bevacizumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized Phase IIb, Open Label Study of Nivolumab or Nivolumab in Combination With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma (GBM).
Nivolumab; Ipilimumab; Bevacizumab

Glioblastoma Multiforme Clinical Trial using I-124-CLR1404

Cellectar Biosciences, Inc. - Recruiting 18 years or older.
- Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme.
I-124-CLR1404

Malignant Glioma, Glioblastoma, or Brain Cancer Clinical Trial using Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.
Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

Recurrent Glioblastoma, or Progressive Glioblastoma Clinical Trial using G-202

GenSpera, Inc. - Recruiting 18 years or older.
- An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With Recurrent or Progressive Glioblastoma.
G-202

Astrocytoma, Central Nervous System Tumor, Glioblastoma, Glioma, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Evaluation of the Natural History of Patients With Tumors of the Central Nervous System.

Glioblastoma Multiforme Clinical Trial using ketogenic diet

Mid-Atlantic Epilepsy and Sleep Center, LLC - Recruiting 18 years to 65 years.
- Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study.
ketogenic diet

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors.
DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Glioma, Glioblastoma, or Brain Tumor, Recurrent Clinical Trial using ANG1005; Bevacizumab

Angiochem Inc - Recruiting 18 years or older.
- A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma.
ANG1005; Bevacizumab

Malignant Neoplasms Brain Clinical Trial using RNA-loaded dendritic cell vaccine; basiliximab

Duke University - Recruiting 18 years or older.
- REGULATory T-Cell Inhibition With Basiliximab (Simulectr) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme.
RNA-loaded dendritic cell vaccine; basiliximab

Glioblastoma Multiforme Clinical Trial using Radiochemotherapy

Technische Universit„t Dresden - Recruiting 18 years or older.
- Observational Study of Impact of [11C]-Methionine PET/MRI as a Tool for Individual Tailoring Postoperative Radiochemotherapy for Patients With Glioblastoma Multiforme.
Radiochemotherapy

Glioblastoma Multiforme Clinical Trial using ALECSAT; Bevacizumab/Irinotecan

CytoVac A/S - Recruiting 18 years or older.
- An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured as Progression Free Survival Compared to Avastin/Irinotecan.
ALECSAT; Bevacizumab/Irinotecan

Glioblastoma Clinical Trial using Blood draw - biomarkers; MRI-guided Laser Heat Ablation (MLA); Doxorubicin

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme.
Blood draw - biomarkers; MRI-guided Laser Heat Ablation (MLA); Doxorubicin

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using Montanide ISA-51/survivin peptide vaccine; sargramostim; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas.
Montanide ISA-51/survivin peptide vaccine; sargramostim; laboratory biomarker analysis

Recurrent Glioblastoma Clinical Trial using BGJ398

Novartis - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma.
BGJ398

Grade IV Astrocytoma, or Glioblastoma Clinical Trial using Temozolomide; folinic acid at pharmacological dose is the escalated drug; High voltage radiation therapy (linear accelerator)

Institut Cancerologie de l'Ouest - Recruiting 18 years to 70 years.
- Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT..
Temozolomide; folinic acid at pharmacological dose is the escalated drug; High voltage radiation therapy (linear accelerator)

Advanced Malignant Glioma, Anaplastic Astrocytomas, or Glioblasto Clinical Trial using AMG 595

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
AMG 595

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Clinical Trial using 3-Tesla magnetic resonance imaging; CEST-MRI; DW-MRI; DCE-MRI; DSC-MRI; IV administration of gadolinium-containing contrast agent

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers.
3-Tesla magnetic resonance imaging; CEST-MRI; DW-MRI; DCE-MRI; DSC-MRI; IV administration of gadolinium-containing contrast agent

Glioblastoma Multiforme, or Gliosarcoma Clinical Trial using AMG 102 with Avastin

Duke University - Recruiting 18 years or older.
- Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.
AMG 102 with Avastin

Glioblastoma Multiforme Clinical Trial using TPI 287; Bevacizumab

Cortice Biosciences, Inc. - Recruiting 18 years or older.
- Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.
TPI 287; Bevacizumab

Glioblastoma (GBM) Clinical Trial using Ketogenic Diet; Radiation therapy; Temozolomide

St. Joseph's Hospital and Medical Center, Phoenix - Recruiting 18 years to 80 years.
- Phase I/II Prospective Trial for Newly Diagnosed GBM, With Upfront Gross or Subtotal Resection, Followed by Ketogenic Diet With Radiotherapy and Concurrent Temodar(R) Chemotherapy Followed by Adjuvant Temodar(R) Chemotherapy..
Ketogenic Diet; Radiation therapy; Temozolomide

Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma Clinical Trial using trebananib; placebo; bevacizumab; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
trebananib; placebo; bevacizumab; pharmacological study; laboratory biomarker analysis

Cancer Clinical Trial using Sativex

GW Pharmaceuticals Ltd. - Recruiting 18 years or older.
- A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma.
Sativex

Recurrent Glioblastoma Clinical Trial using MRI-PET; TMZ-PET

Massachusetts General Hospital - Recruiting 18 years or older.
- A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI.
MRI-PET; TMZ-PET

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Delet Clinical Trial using INC280; Buparlisib

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma.
INC280; Buparlisib

Glioblastoma, Malignant Glioma, Brain Tumors, or Anaplastic Astro Clinical Trial using Stem Cell Radiotherapy (ScRT) and Temozolomide

Beth Israel Medical Center - Recruiting 18 years to 70 years.
- STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Stem Cell Radiotherapy (ScRT) and Temozolomide

Glioblastoma Multiforme Clinical Trial using NovoTTF-100A device; Temozolomide

NovoCure Ltd. - Recruiting 18 years or older.
- A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM..
NovoTTF-100A device; Temozolomide

Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligo Clinical Trial using Toca 511

Tocagen Inc. - Recruiting 18 years to 80 years.
- A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
Toca 511

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Na‹ve Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood A Clinical Trial using oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years.
- A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Glioblastoma Clinical Trial using bevacizumab [Avastin]; temozolomide; Radiotherapy; placebo; SOC

Hoffmann-La Roche - Recruiting 18 years or older.
- A Double-blind, Placebo-controlled, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care (SOC) +/- Continuous Bevacizumab Treatment Following Progression of Disease (PD) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab.
bevacizumab [Avastin]; temozolomide; Radiotherapy; placebo; SOC

Malignant Glioma, or Glioblastoma Clinical Trial using External beam radiotherapy

Rigshospitalet, Denmark - Recruiting 18 years or older.
- Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study.
External beam radiotherapy

Astrocytoma, Oligoastrocytoma, Mixed, Ganglioneuroma, Glioma, Gan Clinical Trial using Irinotecan; Bevacizumab; FDOPA-PET/MRI imaging

Washington University School of Medicine - Recruiting N/A to 21 years.
- Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study.
Irinotecan; Bevacizumab; FDOPA-PET/MRI imaging

First or Second Recurrence of Glioblastoma Clinical Trial using Dovitinib (TKI258)

University Hospital, Bonn - Recruiting 18 years or older.
- The Multi-targeted Tyrosine Kinase Inhibitor Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma.
Dovitinib (TKI258)

Glioblastoma Multiforme Clinical Trial using Bevacizumab; BKM120

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II).
Bevacizumab; BKM120

Glioblastoma Clinical Trial using Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)

Michigan State University - Recruiting 18 years to 90 years.
- Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors.
Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)

Brain Cancer Clinical Trial using Temozolomide; Memantine; Mefloquine; Metformin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme.
Temozolomide; Memantine; Mefloquine; Metformin

Glioblastoma Multiforme Clinical Trial using ABT-414; Temozolomide; Whole Brain Radiation

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme.
ABT-414; Temozolomide; Whole Brain Radiation

Brain and Central Nervous System Tumors Clinical Trial using olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Cancer Research UK - Recruiting 18 years to 70 years.
- A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Clinical Trial using Temozolomide; hypofractionated radiation therapy; bevacizumab; questionnaire administration

Northwestern University - Recruiting 18 years or older.
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Temozolomide; hypofractionated radiation therapy; bevacizumab; questionnaire administration

Recurrent Glioblastoma Clinical Trial using PF-299804 (Dacomitinib)

Grupo Espa¤ol de Investigaci¢n en Neurooncolog¡a - Recruiting 18 years or older.
- A Prospective Multicenter, Open Label, Phase II Pilot Clinical Trial to Evaluate Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation.
PF-299804 (Dacomitinib)

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.
vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

Glioblastoma Clinical Trial using Phase 1 Dose Escalation; Phase 1b; Ancillary Study

Actelion - Recruiting 18 years or older.
- A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide.
Phase 1 Dose Escalation; Phase 1b; Ancillary Study

Brain and Central Nervous System Tumours Clinical Trial using IMA 950 multipeptide based vaccine; Poly ICLC; Temozolomide; radiotherapy; Immunomonitoring

University Hospital, Geneva - Recruiting 18 years or older.
- Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients.
IMA 950 multipeptide based vaccine; Poly ICLC; Temozolomide; radiotherapy; Immunomonitoring

Giant Cell Glioblastoma, Glioblastoma, or Gliosarcoma Clinical Trial using bevacizumab; temozolomide; laboratory biomarker analysis; immunohistochemistry staining method; microarray analysis; DNA methylation analysis

Jonsson Comprehensive Cancer Center - Recruiting 70 years or older.
- Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma.
bevacizumab; temozolomide; laboratory biomarker analysis; immunohistochemistry staining method; microarray analysis; DNA methylation analysis

Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 13 years or older.
- Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, or Hi Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 1 year to 30 years.
- A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

Glioblastoma Clinical Trial using Magnetic Resonance Imaging (MRI)

Medical University of South Carolina - Recruiting 18 years to 80 years.
- Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease.
Magnetic Resonance Imaging (MRI)

Glioblastoma Clinical Trial using BKM120 + temozolomide; BKM120 +temozolomide with/without radiotherapy

Novartis - Recruiting 18 years or older.
- A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.
BKM120 + temozolomide; BKM120 +temozolomide with/without radiotherapy

Glioblastoma Clinical Trial using Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol

Institut Claudius Regaud - Recruiting 18 years or older.
- Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study.
Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol

Recurrent Glioblastoma Clinical Trial using calorie-restricted ketogenic diet and transient fasting; standard nutrition

Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older.
- Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study.
calorie-restricted ketogenic diet and transient fasting; standard nutrition

Advanced Solid Tumors Clinical Trial using E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Eisai Inc. - Recruiting N/A or older.
- An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Glioblastoma Clinical Trial using 5-aminol‚vulinique acid (5-ALA); Placebo

Hospices Civils de Lyon - Recruiting 18 years or older.
- Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional.
5-aminol‚vulinique acid (5-ALA); Placebo

Primary Glioblastoma Clinical Trial using Carbon Ion Radiotherapy; Proton Radiotherapy

University Hospital Heidelberg - Recruiting 18 years or older.
- Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma.
Carbon Ion Radiotherapy; Proton Radiotherapy

Brain and Central Nervous System Tumors Clinical Trial using dasatinib; temozolomide; placebo

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
dasatinib; temozolomide; placebo

Glioblastoma Multiforme, or Anaplastic Astrocytoma Clinical Trial using Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB

Weill Medical College of Cornell University - Recruiting 18 years or older.
- Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB

Glioblastoma Multiforme, or Anaplastic Astrocytoma Clinical Trial using Bevacizumab and Carboplatin

Weill Medical College of Cornell University - Recruiting 18 years or older.
- Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma.
Bevacizumab and Carboplatin

Glioblastoma Multiforme/Anaplastic Astrocytoma Clinical Trial using temozolomide; radiation therapy; stereotactic radiotherapy

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain.
temozolomide; radiation therapy; stereotactic radiotherapy

Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 Clinical Trial using Cilengitide

Northern Sydney and Central Coast Area Health Service - Recruiting 18 years or older.
- Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.
Cilengitide

Primary Glial Neoplasms of Brain, or Glioblastoma Clinical Trial using Aminolevulinic Acid

West Penn Allegheny Health System - Recruiting 18 years or older.
- A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain..
Aminolevulinic Acid

Glioblastoma Clinical Trial using Temozolomide; Radiation Therapy

Center Eugene Marquis - Recruiting 18 years to 70 years.
- Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas..
Temozolomide; Radiation Therapy

GLIOBLASTOMA MULTIFORME, or Brain Neoplasm Clinical Trial

Washington University School of Medicine - Recruiting 18 years to 70 years.
- BIRN (Biomedical Informatics Research Network)Resources Facilitate the Personalization of Malignant Brain Tumor.

Glioblastoma Multiforme Clinical Trial using dynamic contrast enhanced magnetic resonance imaging

Yale University - Recruiting 18 years to 80 years.
- Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities.
dynamic contrast enhanced magnetic resonance imaging